Navigation Links
Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers

DURHAM, N.C., Nov. 17 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the company has begun shipping Dermacyte(TM) Oxygen Concentrate Gel to customers who have pre-ordered through the website. The shipments, which are going out today, cover orders received through early November.

"This is a major milestone event for our company - actually shipping a product to customers and generating revenue as a result," said Chris Stern, company chairman and CEO. "Orders are continuing to come in and we will be shipping on a regular basis. We believe that our new cosmetic line has the potential to be a significant financial contributor and intend to move forward with our aggressive market and product plans and pursue our goal to cover our running costs with product sales."

The gel is a first product of a broad and diverse Dermacyte product line in development. It uses a combination of patented and secret formulations to make the skin appear moist and more youthful.

Dermacyte Oxygen Concentrate Gel can be purchased directly from the company via the secure ordering website at

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. referring to expectations and plans for Dermacyte Oxygen Concentrate Gel that involve risks and uncertainties and reflect the company's judgment as of the date of this release. There can be no assurance that Dermacyte orders will grow or even continue or that Dermacyte sales will cover running costs or contribute any meaningful revenue to the company. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE Oxygen Biotherapeutics, Inc.

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
2. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
3. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
4. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
5. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
6. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
7. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
8. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
9. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
10. Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
(Date:11/25/2015)...  Henry Schein, Inc., the world,s largest provider of ... and animal health practitioners, will unveil at the Greater ... ConnectDental® Pavilion , which brings together for the first ... to help any practice or laboratory enter the digital ... schedule of experts appearing at the Pavilion. --> ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... China , Nov. 25, 2015 ... the "Company") (NYSE: MR ), ... of medical devices worldwide, today announced ... annual general meeting of shareholders at ... 11/F, Grand Century, 193 Prince Edward West ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... 26, 2015 , ... PRMA Plastic Surgery is updating their record books yet ... 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, ... lives and it’s an honor to have served all of these women.” , PRMA ...
(Date:11/26/2015)... (PRWEB) , ... November 26, ... ... online platform for mental health and wellness consultation, has collaborated with Women’s ... holistically address their reader’s queries on topics on mental and emotional well-being ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a ... ™ attracts volunteers together who want to combine talents and resources to help ... in the process. The non-profit launched its first major fundraiser on November 6, ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... companies, has been recognized once again for its stellar workplace culture with the ... Work.” , Medical Solutions’ Cincinnati office was named a finalist in ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, ... Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil ... for the opening of the 5th African Network for Drugs and Diagnostics Innovation, ...
Breaking Medicine News(10 mins):